<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517137</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1537-LYMG</org_study_id>
    <nct_id>NCT03517137</nct_id>
  </id_info>
  <brief_title>Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study</brief_title>
  <acronym>COBRA</acronym>
  <official_title>Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to assess whether treatment adaptation based on a very&#xD;
      early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced&#xD;
      stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing&#xD;
      regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-arm phase II study investigates the value of early FDG-PET-response adapted&#xD;
      BV-based therapy for advanced HL. All patients will receive one cycle of BrAVD followed by an&#xD;
      FDG-PET/CT. Patients with a negative early FDG-PET(Deauville score 1-3) will continue with&#xD;
      five more BrAVD cycles (total six cycles) while patients with a positive FDG-PET should shift&#xD;
      to six cycles of BrECADD.&#xD;
&#xD;
      The hypothesis is that the efficacy will be comparable to the efficacy of BEACOPPesc and&#xD;
      BrECADD, while using the intensive chemotherapy regimen only for those patients who do not&#xD;
      achieve a negative FDG-PET after one cycle.&#xD;
&#xD;
      The choice to assess the treatment sensitivity by PET after a single cycle of BrAVD is based&#xD;
      on results from a recent international multicenter study comparing FDG-PET/CT after one and&#xD;
      two cycles of ABVD chemotherapy in HL. There is no reason to suspect that FDG-PET1 should be&#xD;
      less prognostic after BrAVD than after ABVD.&#xD;
&#xD;
      With this trial, the investigators believe they can add important information about the&#xD;
      optimal treatment of BV-containing first-line treatment for advanced HL, and thus answer&#xD;
      important therapeutic questions that are likely to otherwise remain unanswered even after the&#xD;
      Echelon-1 and HD21 trials reach mature results. This relatively large single-arm phase II&#xD;
      trial of 150 patients will allow a meaningful comparison with the BrAVD and BrECADD regimens&#xD;
      based on modified progression-free survival (primary endpoint) and progression-free survival&#xD;
      (secondary endpoint) respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Progression-free survival (mPFS)</measure>
    <time_frame>4 years after start of first patient in</time_frame>
    <description>Modified PFS (mPFS) is defined as the time interval between the date of treatment start and the date of the first of:&#xD;
Progressive disease (PD)&#xD;
Start of new treatment for Classical Hodgkin Lymphoma (cHL) when not in Complete Response at the end of protocol treatment; in this case, the date of mPFS is the date of the FDG-PET/CT scan at the end of protocol treatment. Switching therapy prior to end of protocol treatment for reasons other than Progressive Disease is not considered an event for mPFS. &quot;End of protocol treatment&quot; refers to completion of the planned protocol treatment with no more than 1 missed cycle, including radiotherapy on PET positive lesions if administered&#xD;
Death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a negative FDG-PET</measure>
    <time_frame>4 years after start of first patient in</time_frame>
    <description>It will be assessed how many patients have a negative FDG-PET image when taken at the end of their first cycle of BrAVD. The BrAVD cycle lasts 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>4 years after start of first patient in</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years after start of first patient in</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events graded according to the National Cancer Institute Common Occurrence of Adverse Events</measure>
    <time_frame>4 years after start of first patient in</time_frame>
    <description>Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated, histologically proven classical Hodgkin lymphoma;&#xD;
&#xD;
          -  Staged by PET with diagnostic-quality CT (i.v. contrast).&#xD;
&#xD;
          -  Clinical stages according to Lugano 2014 and based on FDG/PET CT:&#xD;
&#xD;
               -  Stage IIB with large mediastinal mass &gt; 1/3 max transverse diameter thorax and/or&#xD;
                  extranodal lesion(s)&#xD;
&#xD;
               -  Stage III - IV&#xD;
&#xD;
          -  Consent to participation in translational research:&#xD;
&#xD;
          -  Archival tumor tissue available (15 blank formalin fixed paraffin embedded tissue&#xD;
             samples mounted on APES slides or a tissue block).&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 72 hours prior to the first dose of study treatment.&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should use adequate birth control&#xD;
             measures, as defined by the investigator, during the study treatment period and for at&#xD;
             least 6 months after the last dose of treatment. A highly effective method of birth&#xD;
             control is defined as a method which results in a low failure rate (i.e. less than 1&#xD;
             percent per year) when used consistently and correctly.&#xD;
&#xD;
          -  Female subjects who are breast feeding should discontinue nursing prior to the first&#xD;
             dose of study treatment and until 6 months after the last study treatment.&#xD;
&#xD;
          -  Absence of any medical, psychological, familial, sociological or geographical&#xD;
             condition potentially hampering compliance with the study protocol and follow-up&#xD;
             schedule; those conditions should be discussed with the patient before registration in&#xD;
             the trial&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to&#xD;
             ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cerebral or meningeal disease (HL or any other etiology), including signs or&#xD;
             symptoms of Progressive Multifocal Leukoencenphalopathy&#xD;
&#xD;
          -  Symptomatic neurologic disease compromising normal activities of daily living or&#xD;
             requiring medications&#xD;
&#xD;
          -  Sensory or motor peripheral neuropathy greater than or equal to grade 2 according to&#xD;
             CTCAE version 4.0&#xD;
&#xD;
          -  Any of the following cardiovascular conditions or values:&#xD;
&#xD;
        within 6 months before registration:&#xD;
&#xD;
          -  A left-ventricular ejection fraction &lt;50 percent (at registration)&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV heart failure.&#xD;
&#xD;
          -  Evidence of current uncontrolled cardiovascular conditions, including cardiac&#xD;
             arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence&#xD;
             of acute ischemia or active conduction system abnormalities&#xD;
&#xD;
          -  symptomatic coronary heart disease (stable angina pectoris is allowed)&#xD;
&#xD;
          -  severe uncontrolled hypertension within 2 years before registration&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus (HbA1c &gt; 7.5 percent or a fasting&#xD;
             blood sugar &gt; 200 mg/dL).&#xD;
&#xD;
          -  Any active systemic viral, bacterial, or fungal infection requiring systemic&#xD;
             antibiotics within 2 weeks prior to registration.&#xD;
&#xD;
          -  Known HIV infection, chronic active hepatitis C, HBV positivity (HBsAg + patients;&#xD;
             HBsAg -/HBcAb+/HBV DNA+ patients).&#xD;
&#xD;
        Note: HBsAg-/HBV DNA - patients are eligible; patients who are seropositive due to&#xD;
        vaccination are eligible&#xD;
&#xD;
          -  Concomitant or previous malignancies within the past 5 years with the exception of&#xD;
             adequately treated carcinoma in situ of the cervix , nonmelanoma skin cancer.&#xD;
&#xD;
          -  Previous treatment with anti CD30 antibodies&#xD;
&#xD;
          -  Known hypersensitivity to any excipient contained in Brentuximab Vedotin formulation&#xD;
             and other study drugs. Refer to Summary Product Characteristics for list of&#xD;
             excipients.&#xD;
&#xD;
          -  Concurrent anti-cancer treatment or use of any investigational agent(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hutchings</last_name>
    <role>Principal Investigator</role>
    <affiliation>Past Chair EORTC Lymphoma Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wouter Plattel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Active Member EORTC Lymphoma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Verschuere, PhD</last_name>
    <phone>003227741504</phone>
    <email>1537@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Ka Lung, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Van Den Neste</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Saevels, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherida Woei-A-Jin, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor Aurer, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Copenhagen - Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hutchings, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khaled Hussein, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanne Tonino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7400</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Siemes, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tjeerd Snijders, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Plattel, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden-Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rozemarijn van Rijn, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum (HMC) - Haaglanden MC - locatie Antoniushove</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liane te Boome, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc - Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Stevens, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petronella Lugtenburg, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Locatie Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurens Nieuwenhuizen, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska Curie National Institute of Oncology - National Research Institute</name>
      <address>
        <city>Warsaw</city>
        <zip>02781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Walewski, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues De Oncologia - Francisco Gentil - Centro De Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1099</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Carvalho, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>833</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrej Vranovsky, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blanca Sanchez Gonzalez, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals (Institut Catala D'Oncologia)</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sureda-Balari, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viguria Maria Cruz, PI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced Hodgkin lymphoma</keyword>
  <keyword>brentuximab vedotin</keyword>
  <keyword>phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

